3 Ingredients and Custom Manufacturing, Oral Solid Generics and Large Branded Generics Stocks With a Strong Future Roadmap: Neuland Laboratories, Strides Pharma Science and Dr. Reddy's Laboratories

Pharma ingredient and generic formulation stocks let investors follow companies that make the building blocks of medicines and the finished products themselves. Neuland Laboratories, Strides Pharma Science and Dr. Reddy's Laboratories cover ingredients and custom manufacturing, oral solid generics and large branded generics.

This list covers three pharma ingredient and generic formulation stocks with complete current figures: Neuland Laboratories, Strides Pharma Science and Dr. Reddy's Laboratories. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma Ingredient and Generic Formulation Stocks?

Pharma ingredient and generic formulation stocks are listed pharmaceutical companies that make active ingredients and finished dosage products for regulated markets. Their earnings depend on approvals, launches and long-term supply contracts.

Pharma Ingredient and Generic Formulation Stocks at a Glance

On valuation, Strides Pharma Science and Dr. Reddy's Laboratories trade at a P/E below the industry P/E, while Neuland Laboratories trades above it, which reflects the growth the market already expects. Readers comparing pharma ingredient and generic formulation stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma Ingredient and Generic Formulation Stocks Have a Strong Roadmap in India?

Pharma ingredient and generic formulation stocks have a strong roadmap in India because global drug makers are diversifying supply chains and moving more production to qualified Indian plants.

• Supply chain shift. Buyers are adding Indian partners to diversify sources.
• Custom work. Long-term contracts bring repeat orders.
• Product pipeline. New approvals widen the range sold abroad.

Why Neuland Laboratories Features Among These Pharma Ingredient and Generic Formulation Stocks

Among the pharma ingredient and generic formulation stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Strides Pharma Science Features Among These Pharma Ingredient and Generic Formulation Stocks

Among the contract ingredient pharma shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Why Dr. Reddy's Laboratories Features Among These Pharma Ingredient and Generic Formulation Stocks

Among the three companies on this list, Dr. Reddy's Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.

Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.

The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.

Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.

Neuland Laboratories vs Strides Pharma Science vs Dr. Reddy's Laboratories on Key Financials

The table below sets the three pharma ingredient and generic formulation stocks side by side on revenue, profit and margin, using reported figures.

Neuland Laboratories posts the highest return on equity in this group at 19.4%. Dr. Reddy's Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with pharma ingredient and generic formulation stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma Ingredient and Generic Formulation Stocks

Every theme carries risks that deserve a check before any decision. For these pharma ingredient and generic formulation stocks, the main points are:

• Pricing pressure. Competition can lower prices in common generics.
• Regulatory inspections. Plants must keep meeting global quality standards.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma ingredient and generic formulation stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma Ingredient and Generic Formulation Stocks

Pharma ingredient and generic formulation stocks reward investors who follow approvals, contract wins and plant utilisation together. Neuland Laboratories, Strides Pharma Science and Dr. Reddy's Laboratories each address a different part of the supply chain. Based on the 21 October 2026 close, Neuland Laboratories trades at Rs 18,975, Strides Pharma Science at Rs 1,025.3 and Dr. Reddy's Laboratories at Rs 1,244.5.

Download the Univest iOS App or Univest Android App to track pharma ingredient and generic formulation stocks, set price alerts and get research-backed stock ideas.

What are pharma ingredient and generic formulation stocks?

Ans. Pharma ingredient and generic formulation stocks are listed pharmaceutical companies that make active ingredients and finished dosage products for regulated markets. Their earnings depend on approvals, launches and long-term supply contracts. This list looks at three of them, Neuland Laboratories, Strides Pharma Science and Dr. Reddy's Laboratories, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which pharma ingredient and generic formulation stocks are covered in this list?

Ans. This list covers Neuland Laboratories, Strides Pharma Science and Dr. Reddy's Laboratories. Based on the 21 October 2026 close, Neuland Laboratories traded at Rs 18,975, Strides Pharma Science at Rs 1,025.3 and Dr. Reddy's Laboratories at Rs 1,244.5. Their return on equity ranges from 11.1% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 21.1%.

Why do pharma ingredient and generic formulation stocks have a strong future roadmap in India?

Ans. Pharma ingredient and generic formulation stocks have a strong roadmap in India because global drug makers are diversifying supply chains and moving more production to qualified Indian plants. The main drivers are as follows. Supply chain shift. Buyers are adding Indian partners to diversify sources. Custom work. Long-term contracts bring repeat orders. Product pipeline. New approvals widen the range sold abroad. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

How has Dr. Reddy's Laboratories performed financially?

Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

What risks should investors check before buying pharma ingredient and generic formulation stocks?

Ans. Investors should check a few risks before buying pharma ingredient and generic formulation stocks. Pricing pressure. Competition can lower prices in common generics. Regulatory inspections. Plants must keep meeting global quality standards. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma ingredient and generic formulation stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.